Literature DB >> 20235210

Predictors for remission in rheumatoid arthritis patients: A systematic review.

Wanruchada Katchamart1, Sindhu Johnson, Hsing-Ju Lucy Lin, Veerapong Phumethum, Carine Salliot, Claire Bombardier.   

Abstract

OBJECTIVE: To summarize the potential predictors of remission in patients with rheumatoid arthritis (RA).
METHODS: We performed a systematic review of prognostic studies that identified the predictors of remission in RA patients. Studies were identified in Medline, EMBase, and the Cochrane Registry, and by hand search. We included only studies performing multivariate analysis.
RESULTS: A total of 18 studies from 2,062 citations were included. The following variables were found to be the independent predictors of RA remission: male sex; young age; late-onset RA; short disease duration; nonsmoker; low baseline disease activity; mild functional impairment; low baseline radiographic damage; absence of rheumatoid factor and anti-citrullinated peptide; low serum level of acute-phase reactant, interleukin-2, and RANKL at baseline; MTHFR 677T alleles and 1298C alleles in the methotrexate (MTX)-treated patients; magnetization transfer ratio 2756A allele +/- either the SLC 19A180A allele or the TYMS 3R-del6 haplotype in the MTX plus sulfasalazine combination-treated patients; early treatment with nonbiologic disease-modifying antirheumatic drug (DMARD) combinations; the use of anti-tumor necrosis factor (anti-TNF); the concurrent use of DMARDs in anti-TNF-treated patients; and moderate or good response to treatments at the first 6 months. The magnitude of the association in the individual predictor was diverse among the studies depending on the patient characteristics, the study characteristics, and the variables used to adjust for in the models.
CONCLUSION: A number of independent predictors of remission, i.e., baseline clinical and laboratory characteristics and genetic markers, were summarized. The predictive value of prognostic factors recently identified needs to be confirmed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20235210     DOI: 10.1002/acr.20188

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  49 in total

1.  A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine.

Authors:  Jessica Wojciechowski; Michael D Wiese; Susanna M Proudman; David J R Foster; Richard N Upton
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

2.  The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort.

Authors:  Josefina Durán; Bernard Combe; Jingbo Niu; Nathalie Rincheval; Cécile Gaujoux-Viala; David T Felson
Journal:  Rheumatology (Oxford)       Date:  2015-07-14       Impact factor: 7.580

3.  HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis.

Authors:  Kyung-Eun Lee; Sung-Eun Choi; Haimuzi Xu; Ji-Hyoun Kang; Dong-Jin Park; Shin-Seok Lee
Journal:  Rheumatol Int       Date:  2017-09-27       Impact factor: 2.631

4.  Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis: Results from the Yorkshire Early Arthritis Register.

Authors:  Sarah Twigg; Elizabeth M A Hensor; Paul Emery; Alan Tennant; Ann W Morgan
Journal:  J Rheumatol       Date:  2017-07-01       Impact factor: 4.666

5.  Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients.

Authors:  Damini Jawaheer; Susan Messing; George Reed; Veena K Ranganath; Joel M Kremer; James S Louie; Dinesh Khanna; Jeffrey D Greenberg; Daniel E Furst
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-12       Impact factor: 4.794

6.  SeMet mediates anti-inflammation in LPS-induced U937 cells targeting NF-κB signaling pathway.

Authors:  Yue Shen; Shizhou Yang; Zhongli Shi; Tiao Lin; Hanxiao Zhu; Fanggang Bi; An Liu; Xiaozhou Ying; Haixiao Liu; Kehe Yu; Shigui Yan
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

Review 7.  Selected cytokine pathways in rheumatoid arthritis.

Authors:  Mélissa Noack; Pierre Miossec
Journal:  Semin Immunopathol       Date:  2017-02-17       Impact factor: 9.623

Review 8.  The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies--a systematic review.

Authors:  Hamid J Mohamed; Michael J Sorich; Stefan M Kowalski; Ross McKinnon; Susanna M Proudman; Leslie Cleland; Michael D Wiese
Journal:  Eur J Clin Pharmacol       Date:  2015-02-18       Impact factor: 2.953

9.  Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis.

Authors:  Philipp Guenthoer; Kerstin Fuchs; Gerald Reischl; Leticia Quintanilla-Martinez; Irene Gonzalez-Menendez; Stefan Laufer; Bernd J Pichler; Manfred Kneilling
Journal:  Inflammopharmacology       Date:  2019-04-29       Impact factor: 4.473

Review 10.  cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis.

Authors:  Patrick Vandormael; Patrick Verschueren; Liesbeth De Winter; Veerle Somers
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.